์ฅ์๋ถํฐ๋
์ฅ์๋ถํฐ๋์ ๋น๋จ์์๊ธฐ ํํ๊ทผ ์ด์์ ์ด์ ํญ์ฝ๋ฆฐ์ฑ ์ฝ๋ฌผ์ ๋๋ค. ์์ํ์์๋ ์ฃผ๋ก ๊ฐ์ **๋ฐฐ๋จ๊ทผ ๋ฐ์ฌ ํญ์ง**(๊ณผ๋ฏผ์ฑ ๋ฐฉ๊ด ๋๋ ์ ๋ฐ์ฑ ์์ค๊ธ) ๋ฐ ๊ณ ์์ด ๋ฐฑํ๋ณ ๋ฐ์ด๋ฌ์ค(FeLV)์ ๊ด๋ จ๋ ๋ฐฐ๋จ๊ทผ ๋ถ์์ ์ฑ์ ๊ฐ์ง ๊ณ ์์ด์ ๋ณด์กฐ ์๋ฒ์ผ๋ก ์ฌ์ฉ๋ฉ๋๋ค. ์ฃผ์ ์์ ํฌ์ธํธ: * ๋ฐฉ๊ด ์ฉ์ ์ ์ฆ๊ฐ์ํค๊ณ ์ต์ ๋์ง ์์ ์์ถ์ ๊ฐ์์ํค๋ ์๋ก ์ง๊ฒฝ๊ฒฝ๋ จ์ ๋ก ์์ฉํฉ๋๋ค. * ์ง์ ์ ์ธ ํํ๊ทผ ์ด์ ํน์ฑ๊ณผ ํญ์ฝ๋ฆฐ ํจ๊ณผ๋ฅผ ๋ชจ๋ ๊ฐ์ง๊ณ ์์ต๋๋ค. * **์์ ํ:** ํญ์ฝ๋ฆฐ์ฑ ํน์ฑ ๋๋ฌธ์ ๋ถ๊ต๊ฐ ์ ๊ฒฝ ๊ธด์ฅ ์ ํ๋ก ์ธํด ์ ํ๋ ์ ์๋ ์งํ(์: ๋ น๋ด์ฅ, ์์ฅ๊ด ์ ์ฒด, ๋น๋งฅ์ฑ ๋ถ์ ๋งฅ)์ด ์๋ ํ์์๊ฒ๋ ๊ทน๋๋ก ์ฃผ์ํ์ฌ ์ฌ์ฉํด์ผ ํฉ๋๋ค.
์์ฉ ๊ธฐ์ : Oxybutynin exerts its effects via a dual mechanism of action on the lower urinary tract: 1. **Antimuscarinic (atropine-like) effect:** It competitively antagonizes acetylcholine at postganglionic muscarinic receptors. It has a high affinity for **M1, M2, and M3 receptors**, with M3 being the primary receptor mediating bladder detrusor contraction. 2. **Direct spasmolytic (papaverine-like) effect:** It directly relaxes smooth muscle independent of its anticholinergic activity. These combined actions โ relaxation of the bladder detrusor muscle โ **increased maximum bladder capacity** โ **decreased frequency and amplitude of uninhibited detrusor contractions** โ delayed initial desire to void.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- To decrease bladder contractility (detrusor hyperreflexia) ยท 0.5-1 mg (total dose) ยท PO ยท q8-12h ยท Juvenile animals may require a prolonged dosing interval.
- To decrease bladder contractility (detrusor hyperreflexia) ยท 0.5-1.25 mg per cat ยท PO ยท q8-12h
- Detrusor hyperreflexia ยท 0.5-1.25 mg per cat ยท PO ยท q8-12h
- To decrease bladder contractility (detrusor hyperreflexia) ยท 0.2 mg/kg ยท PO ยท q8-12h ยท Most dogs are dosed at 1.25-3.75 mg (total dose) q12h. Juvenile animals may require a prolonged dosing interval.
- To decrease bladder contractility (detrusor hyperreflexia) ยท 1.25-5 mg (total dose) ยท PO ยท q8-12h
- To decrease bladder contractility (detrusor hyperreflexia) ยท 2-5 mg (total dose) ยท PO ยท q8-12h
- Detrusor hyperreflexia (refractory incontinence) ยท 0.2 mg/kg ยท PO ยท q8-12h
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Obstructive GI tract disease
- Intestinal atony or paralytic ileus
- Angle closure glaucoma
- Hiatal hernia
- Cardiac disease (especially mitral stenosis, arrhythmias, tachycardia, CHF)
- Myasthenia gravis
- Hyperthyroidism
- Prostatic hypertrophy
- Severe ulcerative colitis
- Urinary retention or other obstructive uropathies
- Obstructive GI disease
- Ileus
- Gastrooesophageal reflux
- Glaucoma
- Cardiac disease
- Obstructive urinary disease
์ด์๋ฐ์
- Diarrhea
- Constipation
- Urinary retention
- Hypersalivation
- Sedation
- Dry mouth (xerostomia)
- Dry eyes (keratoconjunctivitis sicca)
- Tachycardia
- Anorexia
- Vomiting
- Weakness
- Mydriasis (pupil dilation)
- Diarrhoea
- Dry mouth
- Dry eyes
- Skin reactions
- Palpitations
์ฝ๋ฌผ ์ํธ์์ฉ
- Anticholinergic agents (e.g., atropine, propantheline, tricyclic antidepressants, antihistamines) ยท May intensify oxybutynin's anticholinergic adverse effects.
- Azole antifungals (e.g., ketoconazole) ยท May inhibit metabolism and increase oxybutynin systemic levels.
- CNS depressants ยท May exacerbate the sedating effects of oxybutynin. ยท moderate
- Macrolide antibiotics (e.g., erythromycin, clarithromycin) ยท May inhibit metabolism and increase oxybutynin systemic levels.
- Anticholinergic agents ยท Additive anticholinergic side effects (e.g., severe constipation, urinary retention, tachycardia) ยท major
- Azole antifungals ยท Potential CYP inhibition leading to increased oxybutynin plasma concentrations ยท moderate
- Macrolide antibiotics ยท Potential CYP inhibition leading to increased oxybutynin plasma concentrations ยท moderate
๋ชจ๋ํฐ๋ง
- Clinical efficacy (reduction in urinary incontinence or frequency)
- Adverse effects (signs of anticholinergic toxicity such as dry mouth, tachycardia, constipation, or urinary retention)
- Urinary output and frequency
- Heart rate
- Bowel movements (monitor for constipation)
- Signs of excessive sedation
๊ณผ์ฉ๋
Overdosage can lead to severe anticholinergic toxicity. * **CNS effects:** Restlessness, excitement, seizures. * **Cardiovascular effects:** Hypertension or hypotension, tachycardia, circulatory failure. * **Other signs:** Fever, nausea, vomiting. * **Massive overdose:** May lead to paralysis, coma, respiratory failure, and death. **Treatment:** Consists of general techniques to limit GI absorption (e.g., emesis, activated charcoal) and supportive care. Intravenous **physostigmine** may be useful to reverse severe anticholinergic signs.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.